Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion, Expanding Psychedelic Drug Portfolio
Eli Lilly has agreed to acquire psychedelic drugmaker AtaiBeckley in a deal worth up to $3.8 billion, including an upfront payment of $2.8 billion and potential additional payments based on performance conditions. The acquisition provides access to BPL-003, a nasal spray showing promise for treating resistant depression.
Topics: Acquisition Pharma Psychedelics